about
Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancerThe expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapyFISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context.Tissue microarrays for miniaturized high-throughput molecular profiling of tumors.TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.Immunoexpression analysis and prognostic value of BLCAP in breast cancerGene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern EuropeLoss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosisMALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer.SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasiaTissue microarray (TMA) applications: implications for molecular medicine.Tissue microarrays for high-throughput molecular pathology.Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck.Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays.Applications of tissue microarray technology.CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.Immunohistochemical analysis of tissue microarrays.Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancerHigh-level βIII-tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome.Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.19q13 amplification is associated with high grade and stage in pancreatic cancer.Expression and prognostic relevance of annexin A3 in prostate cancer.Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness.Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesThe apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability.HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancerStrong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.PPFIA1 and CCND1 are frequently coamplified in breast cancer.
P50
Q27851584-4712946D-9894-45BE-8F3C-75FD8F1AA152Q28245608-EE4B4C3A-A789-47C8-87C9-675FFDE94C85Q28278746-32E1C1EB-589D-481D-935D-F4C8CF536BAAQ30503882-91A44A82-3DE6-45AF-A22B-6FF158D5169FQ30874357-D435F5F0-4565-4041-AFCC-4A3074384688Q31042968-9903075D-7069-4B4E-86C8-B249EE836DE0Q31103058-88D198C2-82BC-4473-A8AF-41D22663B26FQ33217204-BF48DDB4-EBDF-4831-83C8-783056FA96E5Q33305773-EA9D2D14-EC71-46AC-9E37-B11891B4A2B5Q33597980-5C059A91-E05A-465B-8C33-473C77783451Q33606248-65A48336-5B2B-4D58-8EA8-E28C358C904AQ34055653-B4F75CBA-E612-4013-B951-A45DFFD1FCCFQ34254431-C0A9E753-12FA-4778-ADDD-4B5415D7E7CFQ34574636-AE1703D5-ED77-4233-899B-8ECB9D6E33B3Q34580883-20CA80B9-1B82-4FDE-811C-4219D4A42D44Q34820809-138ECC34-F346-41DC-AE63-27831EDBA017Q35572506-73F71A5E-2A0E-4659-8BA3-CE12F885E08DQ35677155-96DECE55-1DA1-499E-A124-71401C20DD03Q35861439-6C1E1B71-4A1A-49CF-AA42-144386C12F5CQ35907359-811D181C-1592-46CD-8610-B70FB08540A6Q36105102-1F31F9D1-E5C9-4CE7-9161-D704E9F6E05AQ36258616-3B9A8C6F-248F-4D9A-A328-2D581A60ABB2Q37778319-238BF42E-46B9-46DE-85EA-FCB8A756E021Q38317100-E1A2C182-960D-412B-A258-30D4370631DDQ38415333-E86E8B2B-AB83-45ED-BA92-8758F300C9A0Q38659673-D145D035-25DE-4273-8999-5AD10B1FF9C1Q38667965-1F60F771-48CB-4E85-9271-4338120DAAA2Q38807025-2BE4F584-2F85-4958-A42F-EC91723496DAQ38906488-2640FEB3-4365-4453-8095-5227A50BB62FQ39500478-4A266926-AE2F-4441-8C96-420AEC1E3ECDQ40045624-21F2295F-5647-4245-8473-0AB98047348FQ40130470-69EE9001-614C-4DD9-972F-CD14D27961B7Q40456561-6148402E-9BB3-49AF-AE97-C2EB209D0A69Q40583228-A5CDB473-6D25-456F-B3BE-8A15614BA956Q40751413-AE35464F-009B-4C03-A524-0DB8CE8981DBQ41251534-6EDE3E01-DAAA-4852-B886-D2D06D6279B4Q41308137-38A67475-7EE9-41F8-B65E-D172ABB3781CQ42414387-B9ACB451-B486-442B-B88A-6DDA62D0D494Q42436743-4AA05299-8B7E-4025-B4EC-94A65A303BFFQ43269857-8B29D868-452B-4636-B08B-7978A7A3FE89
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Ronald Simon
@ast
Ronald Simon
@en
Ronald Simon
@es
Ronald Simon
@sl
type
label
Ronald Simon
@ast
Ronald Simon
@en
Ronald Simon
@es
Ronald Simon
@sl
prefLabel
Ronald Simon
@ast
Ronald Simon
@en
Ronald Simon
@es
Ronald Simon
@sl
P1006
P214
P244
P1006
P106
P21
P214
P244
no2011128127
P31
P496
0000-0003-0158-4258
P734
P735
P7859
lccn-no2011128127